Previous 10 | Next 10 |
Leica Biosystems and Leap Therapeutics Partner on Companion Diagnostic to Advance Care for Cancer Patients Companion diagnostic supports patient identification and enrollment into clinical trials of Leap Therapeutics' DKK1 inhibitor, DKN-01 PR Newswire CAMBRIDGE, M...
Leap Therapeutics to Present at B. Riley Securities Oncology Investor Conference PR Newswire CAMBRIDGE, Mass. , Jan. 24, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology th...
Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to cancer, across the world. The high mortality rates are pr...
Shares of Leap Therapeutics (NASDAQ: LPTX) , a clinical-stage biopharmaceutical company , are surging in response to positive clinical results from a stomach cancer study. Investors excited about the company's lead candidate, DKN-1, drove the stock 10.3% higher as of 12:55 p.m. ...
Tech and biotech stocks on the Nasdaq Stock Market have been taking a beating lately. Narrative-driven growth stocks have fallen out of favor since the start of last December due to the uncertainty created by sky-high inflation rates, the omicron variant, and the Federal Reserve's possi...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re diving right into trading today with the biggest pre-market stock movers for Wednesday! Source: Eric Urquhart/Shutterstock.com Moving stocks this morning are clinical trials, ear...
Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium - DKN-01 plus tislelizumab demonstrated encouraging clinical activity in both first- and second-line advanced gastric or gastroesophageal juncti...
Growth stocks, on balance, have fallen out of favor in recent months. Political gridlock in Washington, D.C., historically high inflation rates, and concerns about an interest rate increase have dampened investors' appetite for risk. This negative sentiment, though, doesn't mean there aren'...
Penny stocks are something that retail traders have flocked to over the last few years. Since the pandemic, people find it isn’t as hard to make money in the stock market as they initially thought. That’s thanks, in part, to these newbies taking time to learn about other w...
Leap Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference PR Newswire CAMBRIDGE, Mass. , Jan. 5, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics,...
News, Short Squeeze, Breakout and More Instantly...
Leap Therapeutics Inc. Company Name:
LPTX Stock Symbol:
NASDAQ Market:
Leap Therapeutics Inc. Website:
Leap Therapeutics Announces $40 Million Private Placement PR Newswire Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development prog...
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium PR Newswire 30% ORR and 93% DCR across heterogenous second-line CRC patients treated with DKN-01 plus bevacizumab and chemotherapy ...